In This Section

Program

Friday, October 21

Registration
3-8 p.m.
Welcome and Opening Keynote Lecture
6:30-7:30 p.m.
Keynote Lecture

Title to be announced
Shannon J. Turley, Genentech, South San Francisco, California

Opening Reception
7:30-9:30 p.m.

Saturday, October 22

Breakfast
7-8 a.m.
Plenary Session 1: Adoptive T Cell Therapy with a Focus on Challenges in Solid Tumors
8-10 a.m.

Engineering CAR T cells for enhanced efficacy and specificity
Robbie Majzner, Stanford University School Medicine, Stanford, California

TCR-gene therapy targeting mutant KRAS
Eric Tran, Providence Cancer Institute, Portland, Oregon

Additional speaker to be announced

Break
10-10:20 a.m.
Plenary Session 2: Next-Generation Checkpoints Beyond PD-1 and CTLA-4
10:20-12:20 p.m.

Title to be announced
Evan J. Lipson, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland

Title to be announced
Zev A. Wainberg, UCLA Medical Center, Santa Monica, California

Title to be announced
Roberta Zappasodi, Weill Cornell Medicine, New York, New York

Lunch on Own / Free Time
12:20-2:30 p.m.
Plenary Session 3: Spatial Analysis of the Tumor Microenvironment
2:30-4:30 p.m.

Title to be announced
Ido Amit, Weizmann Institute of Science, Rehovot, Israel

Title to be announced
Garry P. Nolan, Stanford University School of Medicine, Stanford, California

Title to be announced
Won Jin Ho, Johns Hopkins University, Baltimore, Maryland

Poster Session A / Reception
4:45-7:30 p.m.

Sunday, October 23

Breakfast
7-8 a.m.
Plenary Session 4: Computational Models/AI/Big Data
8-10 a.m.

Title to be announced
Lance L. Munn, Massachusetts General Hospital, Charlestown, MA

Title to be announced
Marta Luksza, Icahn School of Medicine at Mount Sinai, New York, New York

Title to be announced
Benjamin D. Greenbaum, Memorial Sloan Kettering Cancer Center, New York, New York

break
10-10:20 a.m.
Plenary Session 5: Host Factors Regulating Efficacy and Resistance
Session Chair: Jennifer A. Wargo, The University of Texas MD Anderson Cancer Center, Houston, Texas
10:20 a.m.-12:20 p.m.

Title to be announced
Jennifer A. Wargo

Title to be announced
Melody Smith, Stanford University, Stanford, California

An unexpected role for androgens in limiting cancer immunotherapy efficacy
Amy Moran, Oregon Health & Science University, Portland, Oregon

Lunch on own/free time
12:20-2:30 p.m.
Plenary Session 6: Myeloid (and other – maybe) Cells in the Tumor Microenvironment
Session Chair: Thomas F. Gajewski, University of Chicago, Chicago, Illinois
2:30-4:30 p.m.

Title to be announced
Jennifer L. Guerriero, Dana-Farber Cancer Institute, Boston, Massachusetts

Neutrophils as drivers of metastasis: Generation and functions
Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

Title to be announced
Thomas F. Gajewski

Break
4:30-4:45 p.m.
Keynote Lecture
4:45-5:45 p.m.

Sex bias and cancer immunotherapy: Time has come
Zihai Li, The Ohio State University – Pelotonia Institute for Immuno-Oncology, Columbus, Ohio

Poster Session B/Reception
6-8:30 p.m.

Monday, October 24

Breakfast
7-8 a.m.
Plenary Session 7: Mechanisms of IO Toxicity
8-10 a.m.

Title to be announced
Robin Reschke, University of Chicago, Chicago, Illinois

Title to be announced
Javid Moslehi, University of California, San Francisco, California

Title to be announced
Ryan J. Sullivan, Massachusetts General Hospital, Boston, Massachusetts

Break
10-10:20 a.m.
Plenary Session 8: Neoadjuvant IO
10:20-12:20 p.m.

Personalization of neoadjuvant therapy in melanoma – a template for other tumors?
Christian Blank, Netherlands Cancer Institute, Amsterdam, Netherlands

The evolution of neoadjuvant immunotherapy in bladder cancer
Matthew Galsky, Icahn School of Medicine at Mount Sinai, New York, New York

From the clinic to the lab: Investigating mechanisms of response and resistance to
immune checkpoint therapy

Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas

Closing comments and departure
12:20 p.m.